(May 1, 2020 / JNS) The Israel-based biotech company Stero Biotechs has started a small-scale clinical trial at Rabin Medical Center’s Golda Hasharon Campus in Petach Tikvah on the effects of a steroid-Cannabidiol (CBD) treatment on hospitalized COVID-19 patients.
“Steroid treatment is usually the first or second line of treatment for hospitalized patients. CBD enhances the therapeutic effect of steroid treatment and treats the bio-mechanism affected by the virus,” the company said in a press release announcing the clinical trial. “The initial study will evaluate the tolerability, safety and efficacy of the CBD treatment for hospitalized patients with COVID-19 Infections.”
Ten patients will be in the clinical trial; the treatment cycle will be for a few weeks with a follow-up period of the same length. Pending the trial’s success, the company plans to expand to a multi-center clinical trial with an additional 40 hospitalized COVID-19 patients, under FDA clinical trial guidelines and regulations.
“We estimate that our CBD-based treatment can enhance the current treatment of those patients who are suffering life-threatening conditions,” said Stero Biotechs founder and CEO David Bassa.
“Hospitalized COVID-19 patients are mostly being treated with steroids, and our study is planned to demonstrate the benefit of a combined solution with steroid treatments,” he continued. “We are hopeful that this study will lead to faster benefit for the growing number of COVID-19 patients in Israel and around the world.”
Stero Biotechs, founded in 2017 and headquartered in Israel, is a clinical-stage company that focuses on the research and development of novel CBD-based treatment solutions.
Support Jewish Journalism
with 2020 Vision
One of the most intriguing stories of the sudden Coronavirus crisis is the role of the internet. With individuals forced into home quarantine, most are turning further online for information, education and social interaction.
JNS's influence and readership are growing exponentially, and our positioning sets us apart. Most Jewish media are advocating increasingly biased progressive political and social agendas. JNS is providing more and more readers with a welcome alternative and an ideological home.
During this crisis, JNS continues working overtime. We are being relied upon to tell the story of this crisis as it affects Israel and the global Jewish community, and explain the extraordinary political developments taking place in parallel.
Our ability to thrive in 2020 and beyond depends on the generosity of committed readers and supporters. Monthly donations in particular go a long way in helping us sustain our operations. We greatly appreciate any contributions you can make during these challenging times. We thank you for your ongoing support and wish you blessings for good health and peace of mind.